In vivo genome - editing

Search documents
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
ZACKS· 2025-08-08 16:21
Core Insights - Intellia Therapeutics reported a second-quarter 2025 loss of $0.99 per share, which is an improvement from a loss of $1.31 per share in the same quarter last year and better than the Zacks Consensus Estimate of a loss of $1.03 [1][4] - Total revenues for the second quarter of 2025 were $14.2 million, exceeding the Zacks Consensus Estimate of $13 million, and showing significant year-over-year growth driven by collaboration revenues with Regeneron Pharmaceuticals [2][4] - Research and development expenses decreased by 15% year-over-year to $97 million, attributed to lower employee-related expenses and stock-based compensation [4][5] - As of June 30, 2025, Intellia had cash and marketable securities totaling $630.5 million, down from $707.1 million as of March 31, 2025, which is expected to fund operations into the first half of 2027 [6] Pipeline Developments - Intellia is advancing its investigational in vivo genome-editing candidate, nexiguran ziclumeran (nex-z, also known as NTLA-2001), for two indications: ATTR amyloidosis with polyneuropathy and ATTR amyloidosis with cardiomyopathy [7][8] - The Phase III MAGNITUDE study is currently evaluating the safety and efficacy of nex-z, with ongoing enrollment; however, a participant experienced grade 4 liver transaminase elevations, raising safety concerns [9] - Intellia has also initiated the Phase III HAELO study for NTLA-2002, targeting hereditary angioedema, with patient randomization expected to be completed in the third quarter of 2025 [11] Financial Performance - Year-to-date, Intellia's stock has declined by 1.7%, compared to a 1.2% decline in the industry [2] - General and administrative expenses decreased by 14% year-over-year to $27.2 million, primarily due to reduced stock-based compensation [5]
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
ZACKS· 2025-05-09 17:25
Core Viewpoint - Intellia Therapeutics reported a narrower loss per share in Q1 2025 compared to estimates, despite a significant decline in revenues year-over-year, primarily due to lower collaboration revenues from AvenCell [1][2]. Financial Performance - The company incurred a loss of $1.10 per share in Q1 2025, which was better than the Zacks Consensus Estimate of a loss of $1.26 and a slight improvement from a loss of $1.12 per share in the same quarter last year [1]. - Total revenues for Q1 2025 were $16.6 million, reflecting a 42.6% decline year-over-year, but exceeded the Zacks Consensus Estimate of $15 million [2]. - Research and development expenses were $108.4 million, down 3% from the previous year, attributed to lower employee-related expenses and stock-based compensation [4]. - General and administrative expenses decreased by approximately 6.5% year-over-year to $29 million, also due to reduced stock-based compensation and workforce [4]. - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $707.1 million, down from $861.7 million at the end of 2024, which is expected to fund operations into the first half of 2027 [5]. Stock Performance - Shares of Intellia rose by 13.6% on May 8 following the better-than-expected results, although the stock has declined 28.9% year-to-date compared to an 8% decline in the industry [3]. Pipeline Developments - Intellia is collaborating with Regeneron Pharmaceuticals on the investigational in vivo genome-editing candidate, nexiguran ziclumeran (nex-z), which is being studied for ATTR amyloidosis indications [8]. - The phase III MAGNITUDE study for nex-z in patients with ATTR-CM is ongoing, with the FDA granting RMAT designation for this treatment in March [9]. - The first patient was dosed in the phase III MAGNITUDE 2 study for ATTRv-PN in April, with enrollment expected to complete in 2026 [10]. - Another candidate, NTLA-2002, is in the pivotal phase III HAELO study for hereditary angioedema, with the first patient dosed in January 2025 and expected enrollment completion in Q3 2025 [11]. Company Ranking - Intellia currently holds a Zacks Rank 2 (Buy), indicating a favorable outlook compared to other biotech stocks [12].